

Troplex™ Assay for Breast Cancer Biomarkers

The new Troplex™ assay from Yale Pathology Laboratories uses novel technology to quantitatively measure two breast cancer biomarkers – HER2 and TROP2 – both of which are targets for antibody drug conjugate (ADC) therapies in patients with advanced/metastatic breast cancer. The two therapies, Trastuzumab Deruxtecan (TDXd), which targets HER2, and Sacituzumab Govitecan (SG), which targets TROP2, can then be selected based on a quantitative score.

Until the development of the new Troplex™ assay, oncologists could choose between TDXd or SG for patients with advanced/metastatic breast cancer. But the big question is: Which treatment should you prescribe first?

The Troplex™ assay provides defined answers through quantitative measurements of both targets, comparing the two biomarkers to determine which is higher. The Troplex™ assay indicates which biomarker dominates the tumor therefore indicating which drug therapy to administer first.

“Oncologists want to prescribe the best treatment option [for their patients] first—the one that’s most likely to work. Unfortunately, the decision is not always clear. The Troplex™ assay provides a quantitative result to assist the oncologist in deciding which ADC therapy to prescribe in breast cancer.”

–David Rimm, MD, PhD

Director, Yale Pathology Tissue Services

Learn More:

Stephanie Weirman

Director, Reference Services

Business Development

203-464-5518

yalepathologylabs@yale.edu

yalepathologylabs.org

@YalePathology